| 5 | 1/1 | 返回列表 |
| 查看: 2059 | 回復(fù): 7 | ||||
| 當(dāng)前只顯示滿足指定條件的回帖,點(diǎn)擊這里查看本話題的所有回帖 | ||||
古可ぷ榮譽(yù)版主 (文壇精英)
|
[交流]
FDA延遲批準(zhǔn)葛蘭素史克GLP-1藥物阿必魯肽 已有4人參與
|
|||
|
信息來源:http://www.reuters.com/article/2 ... USBRE9710Q620130802 原標(biāo)題:葛蘭素史克糖尿病藥面臨U.S.的延遲批準(zhǔn) (路透社)-英國(guó)最大制藥商周五稱,U.S.監(jiān)管部門已經(jīng)將葛蘭素史克實(shí)驗(yàn)性糖尿病藥物阿必魯肽的批準(zhǔn)決定推遲3個(gè)月至2014年4月15日。 該藥在歐洲按計(jì)劃進(jìn)行申請(qǐng)。該藥用于2型糖尿病,每周治療一次,與諾和諾德利拉魯肽,百時(shí)美施貴寶和阿斯利康的Byetta及 Bydureon屬于同類注射型人胰升血糖素樣肽-1(GLP-1)藥物。 基于臨床試驗(yàn)結(jié)果報(bào)道,業(yè)內(nèi)分析師懷疑阿必魯肽在擁擠的市場(chǎng)能分到多少份額,特別是面臨同線新潛在對(duì)手禮來的度拉魯肽。 GLP-1類藥物在臨床上的受限于人體自身產(chǎn)生的GLP-1 易被體內(nèi)的二肽基肽酶Ⅳ(DPP-Ⅳ)降解,其血漿半衰期不足2分鐘,必須持續(xù)靜脈滴注或持續(xù)皮下注射才能產(chǎn)生療效,大大限制它的臨床應(yīng)用。阿必魯肽為二肽基肽酶拮抗胰高血糖素樣肽二聚體人血清蛋白融合物,半衰期4-7天,在半衰期上比已經(jīng)上市的GLP-1類藥物艾塞那肽和利拉魯肽有優(yōu)勢(shì)。該藥在美日共進(jìn)行22項(xiàng)臨床研究包括有效性安全性以及藥物相互作用等http://clinicaltrials.gov/ct2/re ... lutide&pg=1 ,推遲批準(zhǔn)的原因是?有高人解答否? GlaxoSmithKline diabetes drug faces U.S. approval delay (Reuters) - U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday. A separate filing for the drug in Europe is progressing on schedule. The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca. Based on reported clinical trial results, industry analysts have questioned how well albiglutide will fare in a crowded market - especially with a promising new rival in the pipeline in the form of Eli Lilly's dulaglutide. (Reporting by Ben Hirschler; Editing by Keith Weir) |
新藥動(dòng)態(tài) |

新蟲 (初入文壇)


榮譽(yù)版主 (文壇精英)

| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求生物學(xué)調(diào)劑 +9 | 15172915737 2026-04-01 | 9/450 |
|
|---|---|---|---|---|
|
[基金申請(qǐng)]
請(qǐng)問共同通訊和共同一作的認(rèn)可度問題
10+4
|
psa1234 2026-04-01 | 8/400 |
|
|
[考研] 農(nóng)學(xué)考研求調(diào)劑 +3 | dkdkxm 2026-04-01 | 3/150 |
|
|
[考研] 283求調(diào)劑 +3 | jiouuu 2026-04-02 | 4/200 |
|
|
[考研] 286分調(diào)劑 +20 | Faune 2026-03-30 | 22/1100 |
|
|
[考研] 0710生物學(xué)336分求調(diào)劑 +3 | kiyy 2026-04-01 | 3/150 |
|
|
[考研] 生物學(xué)308分求調(diào)劑(一志愿華東師大) +5 | 相信必會(huì)光芒萬?/a> 2026-03-31 | 6/300 |
|
|
[考研] 一志愿9初試366 本雙非求調(diào)劑 +4 | 運(yùn)氣來得若有似?/a> 2026-04-02 | 4/200 |
|
|
[考研] 考研調(diào)劑 +12 | Amber00 2026-03-31 | 12/600 |
|
|
[考研] 求調(diào)劑,一志愿南京師范大學(xué)計(jì)算機(jī)專碩,初試373,六級(jí)通過, +3 | 計(jì)算機(jī)追夢(mèng)人 2026-04-01 | 3/150 |
|
|
[考研] 350求調(diào)劑 +7 | 阿佳~ 2026-03-31 | 7/350 |
|
|
[考研] 求調(diào)劑:一志愿:南京大學(xué) 專業(yè):0705 總分320 ,本科985,四六級(jí)已過 +3 | lfy760306 2026-03-31 | 3/150 |
|
|
[考研] 346求調(diào)劑 一志愿070303有機(jī)化學(xué) +11 | 蘿卜燉青菜 2026-03-28 | 12/600 |
|
|
[考研] 求調(diào)劑 +9 | akdhjs 2026-03-31 | 10/500 |
|
|
[考研]
|
小羊36 2026-03-30 | 4/200 |
|
|
[考研] 085601 329分調(diào)劑 +6 | yzsa12 2026-03-31 | 6/300 |
|
|
[考研] 297 地理學(xué)070500 復(fù)試求調(diào)劑 +3 | 小圓圈圈ooo 2026-03-30 | 3/150 |
|
|
[考研] 本科新能源科學(xué)與工程,一志愿華理能動(dòng)285求調(diào)劑 +3 | AZMK 2026-03-27 | 5/250 |
|
|
[考研] 一志愿南京航空航天大學(xué)材料學(xué)碩求調(diào)劑 +3 | @taotao 2026-03-28 | 3/150 |
|
|
[考研] 081200-314 +3 | LILIQQ 2026-03-27 | 4/200 |
|